Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
Fluocinolone acetonide intravitreal inserts substantially improved visual acuity for up to 3 years in patients with diabetic macular edema, according to the FAME studies.
The novel basal insulin analog LY2605541 may show advantages over insulin glargine in diabetics, according to researchers.
A study from the University of Calgary’s Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.
Watson Pharmaceuticals Inc. said Friday that it began shipping a generic version of the type 2 diabetes treatment Actos.
ViaCyte is developing a drug delivery system that enables implanted pancreatic progenitor cells to survive and differentiate into functioning insulin-producing islet cells.
Adding insulin degludec to an existing oral antidiabetes regimen produced significantly better glycemic control than did adding sitagliptin in the first head-to-head trial of the two drug classes in patients with type 2 diabetes.
Eli Lilly & Co’s experimental once-weekly diabetes drug dulaglutide proved superior in late-stage clinical trials to three other widely used medicines that are dosed more frequently, the company said on Monday.
There are currently eight categories of oral agents marketed in the US for lowering blood sugar in type 2 diabetes. Each category has different reasons for use, differing efficacies for different individuals, etc.
Aspirin resistance – a concern among patients with type 2 diabetes who may be at high risk of heart disease – may be attenuated by aggressive glucose-lowering therapy, researchers said here.
Recently, a Finnish study evaluated nearly 2,800 nondiabetic individuals, close to 500 of whom were using statins, after they had participated in a year of lifestyle interventions intended to improve their glucose metabolism.
Even within an integrated Veterans Affairs (VA) system with a uniform national formulary and established criteria for drug use, there is substantial variation in the use of thiazolidinediones and long-acting insulin.
Researchers at the University of Michigan have determined how the hormone leptin, an important regulator of metabolism and body weight, interacts with a key receptor in the brain.
In a Finnish study of nearly 3,000 people at high risk of diabetes, those taking statins had higher fasting blood glucose and triglyceride levels and a higher incidence of developing type 2 diabetes than non-statins users.
An antibody can reduce retinal vascular leakage and inflammation in rat models of diabetic retinopathy, according to a study published online Oct. 1 in Diabetes.
An experimental once-a-week drug for type 2 diabetes being developed by Merck & Co proved effective in lowering blood sugar levels in a mid-stage clinical trial, according to data presented on Wednesday.
New data announced at the 48th European Association for the Study of Diabetes (EASD) annual meeting show results of post-hoc pooled analysis of patients with type 2 diabetes aged 65 or older.
Metformin is an oral medicine for Type 2 diabetes that belongs to a drug class known as biguanides. It helps lower blood glucose levels by making muscle and fat cells more sensitive to insulin.
A new drug has been developed which is capable of halting the progression of type II diabetes in animals and actually reversing the disease.
CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.